预约演示
Morris & Dickson will distribute mpox vaccine Jynneos in the US
2024-04-03
疫苗上市批准
Jynneos was a driver of Bavarian Nordic’s 2023 revenue surge. Credits: Richard H Grant/Shutterstock.com
Following Bavarian Nordic’s announcement of the US commercial launch of its mpox (monkeypox) vaccine Jynneos (Imvanex/Imvamune), Morris & Dickson has shared that it will be the first US distributor of the vaccine for the rare viral disease.
According Bavarian Nordicpress release, the Caddo Parish, Louisiana-based wholesaler is receiving the first shipment of vaccines Morris & Dicksond date. Morris & Dickson has a storage and transport capability which is a “uniquviral diseaseof the company’s distribution techniques. As per Jynneos’ label, the vaccine must be kept frozen at -25°C to -15°C and protected from light.
“Jynneos meets a critical public health need and helps ensure equitable access to healthcare, which in turn helps significantly prevent the spread of mpoMorris & Dicksonulations,” said head of Specialty at Morris & Dickson, Layne Martin in the announcement.
The two-dose, subcutaneously administered vaccine regimen, which first gained US Food and Drug Administration (FDA) approval in September 2019, was recommended for routine usage in adults with specific mpoxMorris & Dicksonfactors by the Advisory Committee on Immunization Practices of the US Centers for Disease Control and Prevention (CDC) in October 2023. Previously, the committee recommended the vaccine for this population only at the time of an outbreak.
Jynneos is based on a live non-replicating MVA-BN strain of the modified vacciUS Food and Drug Administration (FDA)replicate in human cells and induces a strong cellular and humoral immune response. Thempox infectioneen a heavy contributor towards Bavarian Nordic’s revenue surge as the company reported a preliminary revenue of $1bn for 2023.
Bavarian Nordic expands access to mpox vaccine in US
Bavarian Nordice key to driving dimpox vaccinecare transformation in US, say experts
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。